| A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension (NCT03492177) | Actelion | 2018-07-23 |
| Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH (NCT03556020) | PhaseBio Pharmaceuticals Inc. | 2018-07-15 |
| Combined Use of Radiofrequency-ablation and Balloon-septostomy in the Creation of a Stable Inter-atrial Communication (NCT03554330) | China National Center for Cardiovascular Diseases | 2018-07-12 |
| A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) (NCT03496207) | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2018-06-13 |
| Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide (NCT07173738) | Bial - Portela C S.A. | 2018-06-11 |
| Oxygen Treatment and Pulmonary Arterial Hypertension (NCT03683082) | George Papanicolaou Hospital | 2018-06-05 |
| 4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Disease (NCT03928002) | Centre Chirurgical Marie Lannelongue | 2018-05-30 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058 (NCT03708146) | Bial - Portela C S.A. | 2018-05-28 |
| Angiogenic Imaging in Pulmonary Arterial Hypertension (NCT03166306) | Brigham and Women's Hospital | 2018-05-01 |
| Effect of BIA 5 1058 on Cardiac Repolarization (NCT03489005) | Bial - Portela C S.A. | 2018-04-09 |
| A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies. (NCT03422328) | Actelion | 2018-04-05 |
| Spironolactone Therapy in Chronic Stable Right HF Trial (NCT03344159) | Ottawa Heart Institute Research Corporation | 2018-04-01 |
| Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil (NCT04994860) | Bial - Portela C S.A. | 2018-03-22 |
| Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers (NCT03464864) | Mannkind Corporation | 2018-03-09 |
| A Systematic Review of Factors Associated With Pulmonary Arterial Hypertension in Systemic Sclerosis (NCT03889509) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2018-03-01 |
| Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH) (NCT03819777) | Maastricht University Medical Center | 2018-03-01 |
| The PAH Platform for Deep Phenotyping in Korean Subjects (NCT03933579) | Gachon University Gil Medical Center | 2018-03-01 |
| Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil (NCT04675944) | Bial - Portela C S.A. | 2018-02-28 |
| Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics (NCT04994119) | Bial - Portela C S.A. | 2018-02-23 |
| Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan (NCT04991207) | Bial - Portela C S.A. | 2018-02-06 |
| Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients (NCT02939599) | Novartis Pharmaceuticals | 2018-02-01 |
| China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization (NCT06954727) | China-Japan Friendship Hospital | 2018-01-01 |
| Pulmonary Hypertension and Anastrozole Trial (NCT03229499) | University of Pennsylvania | 2017-12-07 |
| Biomarkers in Pediatric Congenital Heart Disease and PAH (NCT04130243) | University Medical Center Groningen | 2017-12-05 |
| Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension (NCT03187678) | Actelion | 2017-12-04 |
| Revatio Special Investigation for Long-term Use in Pediatric Patients (NCT03364244) | Viatris Pharmaceuticals Japan Inc | 2017-11-30 |
| Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. (NCT03078907) | Actelion | 2017-11-08 |
| Multi-marker Approach for Risk Assessment in PAH (NCT03954405) | Wuhan Asia Heart Hospital | 2017-11-01 |
| Long-term Outcomes of Pregnant Women With PAH (NCT04053296) | RenJi Hospital | 2017-11-01 |
| A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (NCT02932410) | Actelion | 2017-10-24 |
| A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH (NCT03315507) | PhaseBio Pharmaceuticals Inc. | 2017-10-20 |
| Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension (NCT02999906) | United Therapeutics | 2017-10-01 |
| Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) (NCT03288025) | The Cleveland Clinic | 2017-09-27 |
| Inspiratory Muscle Training in Pulmonary Hypertension (NCT03102294) | Federal University of São Paulo | 2017-09-01 |
| Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States (NCT03197688) | Actelion | 2017-08-03 |
| A Mobile Health Intervention in Pulmonary Arterial Hypertension (NCT03069716) | Vanderbilt University Medical Center | 2017-08-02 |
| Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension (NCT02800941) | Centre Hospitalier Universitaire de Saint Etienne | 2017-07-05 |
| An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension (NCT02882126) | United Therapeutics | 2017-06-01 |
| Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension (NCT03401476) | John Granton | 2017-05-08 |
| Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH (NCT03016468) | United Therapeutics | 2017-05-01 |
| Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension (NCT03365479) | University of Giessen | 2017-05-01 |
| Impact of Rehabilitation Program on PAH Patients Treated With Macitentan. (NCT03045666) | Soroka University Medical Center | 2017-04-15 |
| Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension (NCT02911844) | University of Pennsylvania | 2017-04-10 |
| Absorption, Distribution, Metabolism and Excretion of BIA 5-1058 (NCT04991181) | Bial - Portela C S.A. | 2017-03-31 |
| TReatment Of Pulmonary HYpertension 1-US Study (NCT02835950) | SoniVie Inc. | 2017-03-01 |
| Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA) (NCT02845518) | Central Hospital, Nancy, France | 2017-02-16 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension (NCT02893995) | United Therapeutics | 2017-02-01 |
| The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension (NCT03051763) | University of Giessen | 2017-01-19 |
| Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (NCT02891850) | Bayer | 2017-01-11 |
| Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (NCT02736149) | Eiger BioPharmaceuticals | 2016-12-01 |
| Pulmonary Vascular Disease Phenomics Program PVDOMICS (NCT02980887) | The Cleveland Clinic | 2016-11-01 |
| A Registry for Patients Taking Uptravi (NCT03278002) | Actelion | 2016-11-01 |
| [18F]FES PET/CT in PAH (NCT02899533) | University of Pennsylvania | 2016-07-01 |
| Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension (NCT02782052) | Assistance Publique - Hôpitaux de Paris | 2016-07-01 |
| Crossover Study From Macitentan or Bosentan Over to Ambrisentan (NCT02885012) | Medical University of South Carolina | 2016-06-01 |
| PET/MRI in PAH Patients (NCT03688698) | Medical University of Bialystok | 2016-05-01 |
| The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (NCT02558231) | Actelion | 2016-05-01 |
| Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension (NCT03057028) | Virginia Commonwealth University | 2016-04-01 |
| Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH (NCT02725372) | Bellerophon Pulse Technologies | 2016-04-01 |
| Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension (NCT03105934) | Hospital Universitari Vall d'Hebron Research Institute | 2016-04-01 |
| A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (NCT02664558) | Eiger BioPharmaceuticals | 2016-04-01 |
| Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH (NCT02734953) | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 2016-04-01 |
| Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH (NCT02652429) | Bellerophon Pulse Technologies | 2016-03-01 |
| Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension (NCT02525926) | Centre Hospitalier Universitaire de Nice | 2016-02-04 |
| TReatment Of Pulmonary HYpertension 1 Study (NCT02516722) | SoniVie Inc. | 2016-02-01 |
| The Effect of Adding Exercise Training to Optimal Therapy in PAH (NCT02961023) | National Health Service, United Kingdom | 2016-02-01 |
| Beta-blockers in Pulmonary Arterial Hypertension (NCT02507011) | University of Minnesota | 2016-01-31 |
| Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension. (NCT03476629) | University of Nove de Julho | 2016-01-10 |
| A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension (NCT02676947) | Papworth Hospital NHS Foundation Trust | 2016-01-01 |
| Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions (NCT02691689) | Universitaire Ziekenhuizen KU Leuven | 2015-11-01 |
| Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585 (NCT02746237) | Karos Pharmaceuticals | 2015-11-01 |
| Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058 (NCT04991194) | Bial - Portela C S.A. | 2015-10-12 |
| Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (NCT02471183) | Actelion | 2015-10-12 |
| Pulmonary Hypertension Association Registry (NCT04071327) | Pulmonary Hypertension Association, Inc. | 2015-10-01 |
| Repeatability and Sensitivity to Change of Non-invasive Endpoints in PAH (NCT03841344) | University of Sheffield | 2015-09-15 |
| Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension (NCT03612115) | Dokuz Eylul University | 2015-09-01 |
| The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (NCT02253394) | Brigham and Women's Hospital | 2015-09-01 |
| Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) (NCT02968901) | Actelion | 2015-09-01 |
| Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension (NCT02579954) | Centre Hospitalier Universitaire de Saint Etienne | 2015-08-06 |
| Effect of Food on BIA 5-1058 (NCT04991155) | Bial - Portela C S.A. | 2015-07-20 |
| Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension (NCT02279745) | United Therapeutics | 2015-07-08 |
| Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension (NCT04104490) | University of Florida | 2015-06-06 |
| REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension (NCT02310672) | Actelion | 2015-06-01 |
| Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide (NCT02436512) | Geno LLC | 2015-06-01 |
| Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH (NCT02484807) | Heidelberg University | 2015-05-01 |
| Aerobic Exercise Training in Pulmonary Arterial Hypertension (NCT02371733) | Gazi University | 2015-04-01 |
| Ventricular Reversed Remodeling After LTX in PAH Patients (NCT02391441) | University Medical Center Groningen | 2015-03-01 |
| Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension (NCT02309463) | Actelion | 2015-01-31 |
| Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH (NCT02631421) | Vanderbilt University | 2015-01-01 |
| Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension (NCT05861479) | Central Hospital, Nancy, France | 2015-01-01 |
| Subcutaneous Treprostinil as a Bridge to Lung Transplantation in Severe Pulmonary Hypertension: A Single-Arm Retrospective Study (NCT06605326) | Guangzhou Institute of Respiratory Disease | 2015-01-01 |
| A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH (NCT02284737) | Nanjing First Hospital, Nanjing Medical University | 2014-11-28 |
| Selonsertib in Adults With Pulmonary Arterial Hypertension (NCT02234141) | Gilead Sciences | 2014-11-01 |
| Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry (NCT02249923) | New York Medical College | 2014-10-01 |
| Effects of Oral Sildenafil on Mortality in Adults With PAH (NCT02060487) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2014-09-22 |
| FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan (NCT02958358) | Robert Scott Harris, M.D. | 2014-09-01 |
| Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH (NCT02112487) | Actelion | 2014-06-23 |
| 3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH (NCT02207868) | Regina Steringer-Mascherbauer | 2014-06-01 |
| Right Ventricular Metabolism in Pulmonary Arterial Hypertension (NCT02763735) | Vanderbilt University Medical Center | 2014-06-01 |
| Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT (NCT02036970) | Biogen | 2014-05-31 |